Timon/Adobe StockAlmirall has today announced1 it has entered into an exclusive license agreement with Danish pharmaceutical company Novo Nordisk for the global rights to develop and commercialize NN-8828 (NNC0114-0006), an IL-21 blocking monoclonal antibody. NN-8828 represents a first-in-class agent in dermatology. The license agreement allows Almirall to develop and commercialize NN-8828 in several fields, particularly in immune inflammatory dermatological diseases. Developed by Novo Nordisk and already advanced to phase II in non-dermatological indications, NN-8828 holds promise in inhibiting the pathophysiological functions induced by IL-21 across various immune cells. In return, Novo Nordisk stands to receive an upfront payment, alongside additional development and commercial milestone payments, as well as tiered royalties based on future global sales.

Source: New York Times February 19, 2024 22:06 UTC